ASH Releases New Guidelines for Relapsed/Refractory ALL in Adolescents and Young Adults

The American Society of Hematology (ASH) has unveiled new clinical recommendations for managing relapsed or refractory acute lymphoblastic leukemia (ALL) in adolescents and young adults (AYAs). These guidelines include 8 clinical recommendations and 1 research-only recommendation, placing a strong emphasis on immunotherapy approaches. Published in Blood Advances, the 2026 Guidelines highlight a definitive shift towards immunotherapies, such as blinatumomab and inotuzumab, as compelling alternatives to traditional chemotherapy.

The guidelines also underscore the critical importance of individualized clinical decision-making, always informed by the patient's unique circumstances and preferences.

Why AYAs Are a High-Risk Population

AYAs with ALL are uniquely categorized as a high-risk population. This is primarily due to distinct disease biology, which includes higher rates of T-ALL and Philadelphia-like (Ph-like) ALL when compared to pediatric patients.

Historically, this demographic has faced less favorable outcomes. This disparity is partly attributed to differences between pediatric and adult treatment approaches, ongoing challenges with treatment adherence, and an increased incidence of treatment-related toxicity. Although pediatric-inspired regimens have demonstrably improved survival compared to traditional adult protocols, outcomes in the relapsed or refractory setting for AYAs continue to be suboptimal.

Guideline Development: A Multidisciplinary Approach

To proactively address these persistent treatment gaps, a comprehensive multidisciplinary panel was convened. This panel comprised a diverse group of experts, including hematologists, AYA psychosocial care specialists, pharmacists, methodologists, and crucially, patient representatives.

The panel meticulously developed these guidelines utilizing the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach for rigorous evidence assessment and the formulation of recommendations. Their focus encompassed several key treatment modalities: immunotherapy, targeted therapies, allogeneic hematopoietic stem cell transplantation (allo-HSCT), and central nervous system (CNS)-directed therapy.

Key Recommendations: Immunotherapy Takes Center Stage

For refractory or relapsed ALL, the panel strongly recommends the use of targeted agents like blinatumomab and/or inotuzumab to induce remission. This pivotal recommendation is grounded in their demonstrated efficacy and potentially favorable toxicity profiles compared to conventional chemotherapy.

While the current evidence for survival benefits, remission rates, and reduced toxicity is of low certainty, panelists unanimously consider it highly relevant for guiding current and future treatment strategies.

Specifically, blinatumomab is recommended over chemotherapy for patients experiencing first relapse or refractory B-cell ALL. This recommendation is supported by low-certainty evidence indicating increased remission rates, improved survival, and reduced toxicity. Inotuzumab receives a similar recommendation within this critical setting.

These powerful agents are increasingly being integrated into current treatment strategies. They may also serve as crucial bridging therapies for subsequent treatments, such as allo-HSCT, with the specific approach depending on individual patient and disease factors.

Emerging Therapies and Identified Research Gaps

Emerging therapies, such as daratumumab and CD7-directed CAR T-cell approaches, have shown promising activity, particularly within T-ALL.

However, the panel concluded that current evidence is presently insufficient to support their routine use outside of carefully controlled clinical trials. This applies specifically to AYAs with relapsed or refractory T-ALL, including those who are both nelarabine-naïve and nelarabine-exposed. The panel acknowledged significant progress in immunotherapy for relapsed or refractory T-ALL but stressed that existing data do not yet support widespread adoption beyond the clinical trial setting.

Identified evidence gaps are significant and include:

• A notable lack of direct comparisons between immunotherapies and chemotherapy.
• A shortage of prospective trials specifically designed to determine optimal sequencing, combinations, and treatment durations for AYAs.

Consequently, the guidelines feature a crucial research-only recommendation: When feasible, individuals with relapsed or refractory T-ALL should be offered enrollment in clinical trials evaluating novel agents. This includes therapies such as daratumumab, CAR T-cell therapies, BCL-2 inhibitors, tyrosine kinase inhibitors, and other innovative emerging approaches.

Further research is actively encouraged to assess both short- and long-term outcomes, encompassing vital aspects like toxicity, fertility preservation, and overall health-related quality of life for this vulnerable population.